In 2023, China's HIV-positive tuberculosis treatment success rate stood at 74%. According to forecasts, the treatment success rate is projected to improve steadily to 75% in 2024 and reach 76% by 2025, maintaining this level through 2028. The year-on-year improvement from 2024 to 2025 is approximately 1.3%, with the rate stabilizing afterward. Over the last five years, a compounded annual growth rate (CAGR) of roughly 0.5% can be expected, indicating modest but steady progress.
Future trends to watch for include potential advancements in treatment methodologies, government health initiatives, and the impact of healthcare technology, which could influence further improvements in treatment success rates. Additionally, monitoring any new challenges such as drug resistance patterns or healthcare access issues will be crucial for strategic planning.
